Compare FTHY & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHY | MRVI |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.8M | 449.6M |
| IPO Year | N/A | 2020 |
| Metric | FTHY | MRVI |
|---|---|---|
| Price | $14.00 | $3.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.58 |
| AVG Volume (30 Days) | 176.7K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $192,435,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.66 | $1.67 |
| 52 Week High | $14.74 | $6.21 |
| Indicator | FTHY | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 55.18 |
| Support Level | $14.01 | $3.60 |
| Resistance Level | $14.17 | $3.95 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 41.43 | 50.39 |
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.